Drug · CHEMBL404

TAZOBACTAM

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. TAZOBACTAM. Drugs and targets, record CHEMBL404. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL404

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: TAZOBACTAM; ChEMBL
ChEMBL ID: CHEMBL404; ChEMBL
Type: Small molecule; ChEMBL
Other names: CL 298,741, CL-298741, NSC-759887, YTR-830H; ChEMBL
Other form: TAZOBACTAM SODIUM, CHEMBL1439; Drugs and targets
DrugBank: DB01606; DrugBank
InChIKey: LPQZKKCYTLCDGQ-WEDXCCLWSA-N; ChEMBL
Open Targets' highest stage: Approval, for 8 of its 34 diseases, from ATC, EMA Human Drugs, PMDA and TTD; Open Targets

Targets0

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

None in this release.

Diseases34

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
Sepsis	Approval	PMDA	11	10	https://conductscience.org/library/drugs?q=HP_0100806
infection	Phase 3	ClinicalTrials.gov	10	10	https://conductscience.org/library/drugs?q=EFO_0000544
bacterial infectious disease	Approval	ATC, EMA Human Drugs and TTD	7	4	https://conductscience.org/library/drugs?q=MONDO_0005113
pneumonia	Approval	PMDA	5	4	https://conductscience.org/library/drugs?q=MONDO_0005249
urinary tract infection	Phase 3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0100338
ventilator-associated pneumonia	Phase 3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=EFO_1001865
Fever	Phase 2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=HP_0001945
appendicitis	Phase 2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005649
neutropenia	Phase 2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0001475
septic shock	Phase 3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=EFO_0006834

1 to 10 of 34Source Open Targets

See all 34 diseases

Trials127

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT03269994	Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?	Phase 3	967	2025-10-21	piperacillin-tazobactam	A combination that names it	ClinicalTrials.gov
NCT02070757	Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)	Phase 3	726	2019-05-31	ceftolozane/tazobactam	A combination that names it	ClinicalTrials.gov
NCT01345929	Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis	Phase 3	558	2015-01-15	ceftolozane-tazobactam	A combination that names it	ClinicalTrials.gov
NCT01445678	Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections	Phase 3	494	2015-01-15	ceftolozane-tazobactam	A combination that names it	ClinicalTrials.gov
NCT03019965	Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis		426	2021-08-05	piperacillin/tazobactam	A combination that names it	ClinicalTrials.gov
NCT03830333	Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)	Phase 3	268	2021-10-22	ceftolozane/tazobactam	A combination that names it	ClinicalTrials.gov
NCT01994993	Antibiotic Safety (SCAMP)	Phase 2/3	260	2018-02-27	piperacillin-tazobactam	A combination that names it	ClinicalTrials.gov
NCT03289351	Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis	Phase 4	162	2024-01-12	tazobactam	Its name	ClinicalTrials.gov
NCT03230838	MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)	Phase 2	134	2021-12-01	ceftolozane/tazobactam	A combination that names it	ClinicalTrials.gov
NCT01147640	Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections	Phase 2	122	2015-01-16	tazobactam	Its name	ClinicalTrials.gov

1 to 10 of 127

See all 127 trials

Comparisons in its trials71

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
CXA-201 as Treatment for cUTI vs Levofloxacin as Treatment for cUTI: serious adverse events	15 of 533	18 of 535	1,068	NCT01345929	Trial comparisons
CXA-201 and Metronidazole as Treatment for cIAI vs Meropenem as Treatment for cIAI: serious adverse events	39 of 482	36 of 497	979	NCT01445678	Trial comparisons
Cefoxitin vs Piperacillin-tazobactam: Number of Participants Evaluated for the Effectiveness of Cefoxitin as a Surgical Antibiotic Prophylaxis.	400 of 400	378 of 378	778	NCT03269994	Trial comparisons
Cefoxitin vs Piperacillin-tazobactam: deaths from any cause	10 of 400	5 of 378	778	NCT03269994	Trial comparisons
Cefoxitin vs Piperacillin-tazobactam: serious adverse events	10 of 400	5 of 378	778	NCT03269994	Trial comparisons
Ceftolozane/Tazobactam vs Meropenem: deaths from any cause	105 of 361	101 of 359	720	NCT02070757	Trial comparisons
Ceftolozane/Tazobactam vs Meropenem: serious adverse events	152 of 361	129 of 359	720	NCT02070757	Trial comparisons
Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem vs Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem: Number of Participants With Clinical Response	178 of 201	169 of 202	403	NCT03019965	Trial comparisons
Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem vs Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem: Number of Participants With Adverse Events	1 of 201	3 of 202	403	NCT03019965	Trial comparisons
Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem vs Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem: deaths from any cause	17 of 201	19 of 202	403	NCT03019965	Trial comparisons

1 to 10 of 71

See all 71 comparisons in its trials

Papers from its trials108

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40360262	RESULT	1	PubMed
40261382	RESULT	1	PubMed
37888913	RESULT	1	PubMed
37877585	RESULT	1	PubMed
37837651	RESULT	1	PubMed
37256341	RESULT	1	PubMed
37039790	RESULT	1	PubMed
37000942	RESULT	1	PubMed
36689671	RESULT	1	PubMed
36525245	RESULT	1	PubMed

1 to 10 of 108

See all 108 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL404

GET https://conductscience.org/api/drugs/v1/CHEMBL404/diseases?page=2

API reference For AI assistants